- Home
- GDTC vs APM Comparison
GDTC vs APM Comparison
Compare GDTC & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDTC
- APM
- Stock Information
- Founded
- GDTC 2018
- APM 2010
- Country
- GDTC Singapore
- APM United Kingdom
- Employees
- GDTC N/A
- APM N/A
- Industry
- GDTC Biotechnology: Pharmaceutical Preparations
- APM Biotechnology: Pharmaceutical Preparations
- Sector
- GDTC Health Care
- APM Health Care
- Exchange
- GDTC Nasdaq
- APM Nasdaq
- Market Cap
- GDTC 21.5M
- APM 18.9M
- IPO Year
- GDTC 2023
- APM 2018
- Fundamental
- Price
- GDTC $2.17
- APM $2.09
- Analyst Decision
- GDTC Buy
- APM
- Analyst Count
- GDTC 1
- APM 0
- Target Price
- GDTC $5.00
- APM N/A
- AVG Volume (30 Days)
- GDTC 21.1K
- APM 437.5K
- Earning Date
- GDTC 01-01-0001
- APM 04-30-2025
- Dividend Yield
- GDTC N/A
- APM N/A
- EPS Growth
- GDTC N/A
- APM N/A
- EPS
- GDTC N/A
- APM N/A
- Revenue
- GDTC $573,193.00
- APM N/A
- Revenue This Year
- GDTC $5.37
- APM N/A
- Revenue Next Year
- GDTC N/A
- APM N/A
- P/E Ratio
- GDTC N/A
- APM N/A
- Revenue Growth
- GDTC 63.03
- APM N/A
- 52 Week Low
- GDTC $1.65
- APM $0.46
- 52 Week High
- GDTC $4.05
- APM $7.49
- Technical
- Relative Strength Index (RSI)
- GDTC 62.97
- APM 54.81
- Support Level
- GDTC $1.95
- APM $1.74
- Resistance Level
- GDTC $2.30
- APM $2.45
- Average True Range (ATR)
- GDTC 0.09
- APM 0.19
- MACD
- GDTC 0.01
- APM 0.04
- Stochastic Oscillator
- GDTC 70.29
- APM 50.63
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in one segment: research and development. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.